Current Treatment Options in Neurology

, Volume 15, Issue 4, pp 396–409

Treatment of Restless Legs Syndrome

MOVEMENT DISORDERS (O SUCHOWERSKY, SECTION EDITOR)

Opinion statement

Restless legs syndrome (RLS) is a common, sensorimotor, circadian sleep disorder characterized by the urge to move the legs, particularly at nighttime. It is important to differentiate primary and secondary RLS from other conditions, which can mimic the symptoms of RLS, in particular neuropathy and cramps. Despite considerable advances, the understanding of RLS pathophysiology remains incomplete. Many hypotheses focus on central nervous system structures, although there is increasing evidence that peripheral structures may also be important. There is insufficient evidence at the moment to recommend changes in lifestyle, nutritional supplements and any specific nonpharmacologic treatments. The first-line drugs continue to be dopaminergic medications, including pramipexole, ropinirole, rotigotine transdermal patch and levodopa. However, the phenomenon of RLS augmentation, a paradoxical worsening of symptoms by dopaminergic treatment remains as major problem in treatment of RLS, and prevention of augmentation is one of the main goals in the management of RLS. RLS requires treatment only if it has a significant impact on the patient’s nighttime sleep or daily activities. Doses of dopamine agonists should be kept to the minimum required for acceptable symptom reduction. Augmentation may require treatment withdrawal, with prescription of alternate medication. Alternative or additional pharmacologic treatment with a lower level of overall quality of evidence includes opioids (codeine, tramadol, and oxycodone) and anticonvulsants (gabapentin, gabapentin enacarbil, and pregabalin). The choice of the medication should be based on the severity of RLS and the effectiveness of medication for the short-term or long-term treatment of RLS. Iron deficiency must be identified at diagnosis; treatment may improve RLS symptoms and potentially may lower risk of augmentation. There is no clear evidence for treatment of secondary RLS, but agents used in primary RLS should be tried. Comparative long-term trials are required to assess differences in efficacy and augmentation rates between medications used for treatment of RLS.

Keywords

Restless legs syndrome RLS Treatment Dopaminergics Dopamine agonists Augmentation Levodopa Opioids Anticonvulsants Iron 

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance•• Of major importance

  1. 1.
    Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4:101–19.PubMedCrossRefGoogle Scholar
  2. 2.
    Bjorvatn B, Leissner L, Ulfberg J, et al. Prevalence, severity and risk factors of restless legs syndrome in the general adult population in two Scandinavian countries. Sleep Med. 2005;6:307–12.PubMedCrossRefGoogle Scholar
  3. 3.
    Berger K, Luedemann J, Trenkwalder C, John U, Kessler C. Sex and the risk of restless legs syndrome in the general population. Arch Intern Med. 2004;164:196–202.PubMedCrossRefGoogle Scholar
  4. 4.
    Zucconi M, Ferini-Strambi L. Epidemiology and clinical findings of restless legs syndrome. Sleep Med. 2004;5:293–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Trenkwalder C, Paulus W. Restless legs syndrome: pathophysiology, clinical presentation and management. Nat Rev Neurol. 2010;6:337–46.PubMedCrossRefGoogle Scholar
  6. 6.
    Winkelmann J, Muller-Myhsok B, Wittchen HU, et al. Complex segregation analysis of restless legs syndrome provides evidence for an autosomal dominant mode of inheritance in early age at onset families. Ann Neurol. 2002;52:297–302.PubMedCrossRefGoogle Scholar
  7. 7.
    Allen RP, Earley CJ. Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom-onset. Sleep Med. 2000;1:11–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Hattan E, Chalk C, Postuma RB. Is there a higher risk of restless legs syndrome in peripheral neuropathy? Neurology. 2009;72:955–60.PubMedCrossRefGoogle Scholar
  9. 9.
    Hening WA, Walters AS, Wagner M, et al. Circadian rhythm of motor restlessness and sensory symptoms in the idiopathic restless legs syndrome. Sleep. 1999;22:901–12.PubMedGoogle Scholar
  10. 10.
    Trenkwalder C, Hening WA, Walters AS, et al. Circadian rhythm of periodic limb movements and sensory symptoms of restless legs syndrome. Mov Disord. 1999;14:102–10.PubMedCrossRefGoogle Scholar
  11. 11.
    Michaud M, Dumont M, Selmaoui B, et al. Circadian rhythm of restless legs syndrome: relationship with biological markers. Ann Neurol. 2004;55:372–80.PubMedCrossRefGoogle Scholar
  12. 12.
    Garcia-Borreguero D, Allen RP, Benes H, et al. Augmentation as a treatment complication of restless legs syndrome: concept and management. Mov Disord. 2007;22 Suppl 18:S476–84.PubMedCrossRefGoogle Scholar
  13. 13.
    Allen R. Dopamine and iron in the pathophysiology of restless legs syndrome (RLS). Sleep Med. 2004;5:385–91.PubMedCrossRefGoogle Scholar
  14. 14.
    Connor JR, Boyer PJ, Menzies SL, et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology. 2003;61:304–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Winkelmann J, Schormair B, Lichtner P, et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet. 2007;39:1000–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Trenkwalder C, Paulus W. Why do restless legs occur at rest? Pathophysiology of neuronal structures in RLS. Neurophysiology of RLS (part 2). Clin Neurophysiol. 2004;115:1975–88.PubMedCrossRefGoogle Scholar
  17. 17.
    Paulus W, Trenkwalder C. Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome. Lancet Neurol. 2006;5:878–86.PubMedCrossRefGoogle Scholar
  18. 18.
    Gemignani F, Brindani F, Vitetta F, Marbini A, Calzetti S. Restless legs syndrome in diabetic neuropathy: a frequent manifestation of small fiber neuropathy. J Peripher Nerv Syst. 2007;12:50–3.PubMedCrossRefGoogle Scholar
  19. 19.
    Polydefkis M, Allen RP, Hauer P, et al. Subclinical sensory neuropathy in late-onset restless legs syndrome. Neurology. 2000;55:1115–21.PubMedCrossRefGoogle Scholar
  20. 20.
    Rios Romenets S, Dauvilliers Y, Cochen De Cock V, et al. Restless legs syndrome outside the blood-brain barrier - exacerbation by domperidone in Parkinson's disease. Parkinsonism Relat Disord. 2013;19:92–4.Google Scholar
  21. 21.
    O'Keeffe ST, Gavin K, Lavan JN. Iron status and restless legs syndrome in the elderly. Age Ageing. 1994;23:200–3.PubMedCrossRefGoogle Scholar
  22. 22.••
    Aurora RN, Kristo DA, Bista SR, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults-an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. Sleep. 2012;35:1039–62. This article provides an update of previous review of American Academy of Sleep Medicine in the treatments of RLS using a systematic literature review and meta-analyses.PubMedGoogle Scholar
  23. 23.••
    Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, et al. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. Eur J Neurol. 2012;19:1385–96. This article is the European guidelines, which provides recently revised evidence-based recommendations for the treatment for RLS.PubMedCrossRefGoogle Scholar
  24. 24.
    Cornelius JR, Tippmann-Peikert M, Slocumb NL, Frerichs CF, Silber MH. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep. 2010;33:81–7.PubMedGoogle Scholar
  25. 25.
    Ondo WG, Lai D. Predictors of impulsivity and reward seeking behavior with dopamine agonists. Parkinsonism Relat Disord. 2008;14:28–32.PubMedCrossRefGoogle Scholar
  26. 26.
    Driver-Dunckley ED, Noble BN, Hentz JG, et al. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol. 2007;30:249–55.PubMedCrossRefGoogle Scholar
  27. 27.
    O'Sullivan SS, Evans AH, Lees AJ. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs. 2009;23:157–70.PubMedCrossRefGoogle Scholar
  28. 28.
    Tippmann-Peikert M, Park JG, Boeve BF, Shepard JW, Silber MH. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology. 2007;68:301–3.PubMedCrossRefGoogle Scholar
  29. 29.
    Quickfall J, Suchowersky O. Pathological gambling associated with dopamine agonist use in restless legs syndrome. Parkinsonism Relat Disord. 2007;13:535–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Williams AM, Garcia-Borreguero D. Management of restless legs syndrome augmentation. Curr Treat Options Neurol. 2009;11:327–32.PubMedCrossRefGoogle Scholar
  31. 31.
    Hogl B, Garcia-Borreguero D, Kohnen R, et al. Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study. J Neurol. 2010;257:230–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Collado-Seidel V, Kazenwadel J, Wetter TC, et al. A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms. Neurology. 1999;52:285–90.PubMedCrossRefGoogle Scholar
  33. 33.
    Hogl B, Garcia-Borreguero D, Trenkwalder C, et al. Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome. Sleep Med. 2011;12:351–60.PubMedCrossRefGoogle Scholar
  34. 34.
    Walters AS, Ondo WG, Dreykluft T, et al. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord. 2004;19:1414–23.PubMedCrossRefGoogle Scholar
  35. 35.
    Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomized, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry. 2004;75:92–7.PubMedGoogle Scholar
  36. 36.
    Garcia-Borreguero D, Grunstein R, Sridhar G, et al. A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome. Sleep Med. 2007;8:742–52.PubMedCrossRefGoogle Scholar
  37. 37.•
    Oertel W, Trenkwalder C, Benes H, et al. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol. 2011;10:710–20. This is standard large and recent clinical trial, which test new option for treatment of moderate to severe primary RLS.PubMedCrossRefGoogle Scholar
  38. 38.
    Davis BJ, Rajput A, Rajput ML, Aul EA, Eichhorn GR. A randomized, double-blind placebo-controlled trial of iron in restless legs syndrome. Eur Neurol. 2000;43:70–5.PubMedCrossRefGoogle Scholar
  39. 39.
    Trenkwalder C, Hogl B, Benes H, Kohnen R. Augmentation in restless legs syndrome is associated with low ferritin. Sleep Med. 2008;9:572–4.PubMedCrossRefGoogle Scholar
  40. 40.•
    Allen RP, Adler CH, Du W, et al. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centered, placebo-controlled preliminary clinical trial. Sleep Med. 2011;12:906–13. This is a big, standard large and recent RCT's, which provides new option of treatment of RLS with intravenous iron salt.PubMedCrossRefGoogle Scholar
  41. 41.
    Earley CJ, Heckler D, Allen RP. The treatment of restless legs syndrome with intravenous iron dextran. Sleep Med. 2004;5:231–5.PubMedCrossRefGoogle Scholar
  42. 42.
    Ondo WG. Intravenous iron dextran for severe refractory restless legs syndrome. Sleep Med. 2010;11:494–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Auerbach M, Al TK. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease. Kidney Int. 2008;73:528–30.PubMedCrossRefGoogle Scholar
  44. 44.
    Horiguchi J, Yamashita H, Mizuno S, et al. Nocturnal eating/drinking syndrome and neuroleptic-induced restless legs syndrome. Int Clin Psychopharmacol. 1999;14:33–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Pinninti NR, Mago R, Townsend J, Doghramji K. Periodic restless legs syndrome associated with quetiapine use: a case report. J Clin Psychopharmacol. 2005;25:617–8.PubMedCrossRefGoogle Scholar
  46. 46.
    Kang SG, Park YM, Choi JE, et al. Association study between antipsychotic-induced restless legs syndrome and polymorphisms of monoamine oxidase genes in schizophrenia. Hum Psychopharmacol. 2010;25:397–403.PubMedCrossRefGoogle Scholar
  47. 47.
    Kang SG, Lee HJ, Jung SW, et al. Characteristics and clinical correlates of restless legs syndrome in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1078–83.PubMedCrossRefGoogle Scholar
  48. 48.
    Aurora RN, Morgenthaler TI. On the goodness of recommendations: the changing face of practice parameters. Sleep. 2010;10:1273–6.Google Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of NeurologyMcGill University, Montreal General HospitalMontrealCanada

Personalised recommendations